Study shows that cycling to work could cut risk of cancer by 45 percent
May 2, 2017
A World Without Hepatitis C | BioPlus Specialty Pharmacy
May 2, 2017
Show all

How Biotech is Mastering Multiple Sclerosis: A Review

Ocrevus is a medication now approved for primary-progressive MS.

With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard to bring their own therapeutics for the disease to market.

Multiple sclerosis (MS) is an autoimmune disease that affects the nervous system, and around 2 million people around the world live with this condition. Most people have the relapsing form (RRMS), which is marked by periodic inflammatory attacks, followed by phases of partial or complete recovery.

Around 65 percent of patients with this type of MS will develop secondary-progressive MS (SPMS), which leads to progressively worsening neurological function. Another 10 to 15 percent of people will be diagnosed with primary-progressive MS (PPMS), which also leads to gradually worsening symptoms, but without first having the relapsing form of the disease.

Read full article: How Biotech is Mastering Multiple Sclerosis: A Review

Read Full Article: How Biotech is Mastering Multiple Sclerosis: A Review

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.